Evidence map›Paper›PMID 28800765›Full record

Trial reportBMC surgery2017

Therapeutic effects of flurbiprofen axetil on mesenteric traction syndrome: randomized clinical trial.

Hidemasa Takahashi, Dai Shida, Kyoko Tagawa, Ryo Iwamoto, Makoto Arita, Hiroyuki Arai, Takeo Suzuki

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hidemasa TakahashiDepartment of Anesthesiology, Tokyo Metropolitan Bokutoh Hospital, 4-23-15, Koto-bashi, Sumida-ku, Tokyo, 130-8575, Japan. bokutouma@yahoo.co.jp.
Dai ShidaColorectal Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kyoko TagawaDepartment of Anesthesiology, Tokyo Metropolitan Bokutoh Hospital, 4-23-15, Koto-bashi, Sumida-ku, Tokyo, 130-8575, Japan.
Ryo IwamotoBusiness-Academia Collaborative Laboratory, Graduate School of Pharmaceutical Sciences, University of Tokyo, 37-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Makoto AritaDepartment of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Hiroyuki AraiDepartment of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Takeo SuzukiDepartment of Anesthesiology, Tokyo Metropolitan Bokutoh Hospital, 4-23-15, Koto-bashi, Sumida-ku, Tokyo, 130-8575, Japan.
The University of Tokyo · JPTokyo Metropolitan Bokutoh Hospital · JPTokyo National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to reveal the appropriate timing for the intravenous administration of flurbiprofen axetil for preventing mesenteric traction syndrome (MTS), caused by prostacyclin release.

methodsIn this prospective, randomized, clinical study, forty-five patients who were undergoing elective surgery for colorectal cancer via laparotomy were enrolled. Patients were randomly divided into 3 groups: a preoperative group (n = 16) receiving flurbiprofen axetil directly before surgery; a post-MTS group (n = 14) receiving following MTS onset; and a control group (n = 15) who were not administered flurbiprofen axetil. 6-keto-PGF1α, a stable metabolite of prostacyclin, levels were measured and mean blood pressures were recorded.

resultsIn the preoperative group, 6-keto-PGF1α levels did not increase, blood pressure levels did not decrease, and no facial flushing was observed. In both the post-MTS and control groups, 6-keto-PGF1α levels increased markedly after mesenteric traction and blood pressure decreased significantly. The post-MTS group exhibited a faster decreasing trend in 6-keto-PGF1α levels and quick restore of the mean blood pressure, and the use of vasopressors and phenylephrine were lower than that in the control group.

conclusionsEven therapeutic administration of flurbiprofen axetil after the onset of MTS has also effects on MTS by suppressing prostacyclin production.

trial registrationClinical trial number: UMIN000009111 . (Registered 14 October 2012).

Indexed as

6-Ketoprostaglandin F1 alphaAgedAnti-Inflammatory Agents, Non-SteroidalBlood PressureColorectal NeoplasmsEpoprostenolFemaleFlurbiprofenFlushingHemodynamicsHumansHypotensionInfusions, IntravenousIntraoperative ComplicationsLaparotomyMale6-Ketoprostaglandin F1 alphaAnti-Inflammatory Agents, Non-SteroidalEpoprostenolFlurbiprofenflurbiprofen axetil6-keto-prostaglandin F1αColorectal cancerFlurbiprofen axetilMesenteric traction syndromeProstacyclin

Identifiers

PMID28800765
PMCPMC5553989
OpenAlexW2742966836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.